| Abstract |
To investigate the effect and prognosis of fluoxetine in patients with depression after cerebral infarction. METHODS: One hundred patients with depression after cerebral infarction admitted to our hospital from January 2017 to January 2019 were enrolled in the study. They were randomly divided into groups and treated with conventional regimens such as blood pressure control and lipid regulation. Control group, n=50) and on the basis of this, plus fluoxetine intervention (observation group, n=50) total effective rate, depression score, neurological deficit, cognitive function, quality of life score, adverse reactions The rate is expanded. RESULTS: The total effective rate of patients with depression after cerebral infarction was 94.00% in the observation group, which was statistically significant compared with the control group (P<0.05). There was no difference in the depression score before treatment. >0.05), the test value after intervention was lower than before, and the observation group was more significant than the control group, the difference was statistically significant (P<0.05); before treatment, neurological deficit, cognitive function, There was no difference in the quality of life scores (P>0.05). After treatment, the neurological deficit scores were lower than before, and the cognitive function and quality of life scores were higher than before, and the test values were lower than the control group. The degree of elevation was more significant, and the difference was statistically significant (P<0.05). In the observation group, only 1 case of abdominal pain, the adverse reaction rate was 2%, but the symptoms were mild, the patient was tolerated, and the symptomatic treatment improved. There was no obvious adverse reaction in the control group. There was no significant difference in the adverse reaction rate between the groups (P>0.05). . Conclusion: For patients with clinically treated cerebral infarction complicated with depression, the addition of fluoxetine on the basis of conventional treatment can significantly improve the total effective rate, improve the negative psychological state of depression, and promote neurological and cognitive functions. Recovery, enhanced quality of life, and high security.
|